Kura Oncology, Inc. key statistics and ratios

In fiscal 2025, Kura Oncology, Inc. had return on equity of -94.8%, an operating margin of -449.9%, debt equal to 5.6% of equity and a current ratio of 6.06. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.

Financial ratios

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Kura Oncology, Inc.: financial ratios, annual
Fiscal year	2023Dec 2023	2024Dec 2024	2025Dec 2025	LTMJun 2026
Operating margin	—	−358.5%	−449.9%	−411.9%
Net margin	—	−322.9%	−412.9%	−384.3%
Free-cash-flow margin	—	248.4%	−104.8%	−152.1%
Return on equity	−38.4%	−42.9%	−94.8%	—
Return on assets	−34.0%	−28.8%	−37.2%	−44.8%
Asset turnover	—	0.09	0.09	0.12
Current ratio	12.26	9.46	6.06	4.73
Debt to equity	2.3%	2.3%	5.6%	20.2%
Interest cover (operating income ÷ interest)	n/m	n/m	n/m	n/m
R&D as % of revenue	—	315.4%	372.1%	336.0%
SG&A as % of revenue	—	143.1%	177.8%	—
Capital spending as % of revenue	—	0.9%	9.8%	7.3%

US$ thousands unless shown otherwise. Fiscal quarters.

Kura Oncology, Inc.: financial ratios, quarterly
Quarter	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q1Mar 2026	2026 Q2Jun 2026
Gross margin	—	—	—	—	98.6%	98.8%
Operating margin	−458.6%	−475.3%	−385.5%	−497.6%	−431.5%	−349.8%
Net margin	−407.1%	−432.5%	−357.2%	−467.2%	−401.5%	−327.3%
Free-cash-flow margin	−511.9%	−197.8%	−400.9%	663.1%	−470.7%	−302.8%
Current ratio	8.07	6.16	5.12	6.06	6.15	4.73
Debt to equity	2.6%	3.1%	4.0%	5.6%	9.0%	20.2%
R&D as % of revenue	396.7%	410.7%	327.3%	371.5%	357.3%	296.5%
SG&A as % of revenue	161.9%	164.6%	—	—	172.8%	152.1%

Returns use average equity or assets over the year. Return on equity is left blank when equity is negative or so small that the ratio says nothing (above ±200%); interest cover is left blank above 200 times. Price-based ratios such as P/E are on the valuation page.

Financial health

4 of 7 checks passed · June 30, 2026

What it owns · $588m

Short-term assets $559mLonger-term assets $28m

What it owes, and who funded it · $588m

Short-term liabilities $118mLonger-term liabilities $421mShareholders' equity $48m

Short-term assets cover short-term liabilities $559m of assets due within a year against $118m of liabilities due within a year.
Short-term assets cover long-term liabilities $559m short-term assets against $421m of longer-dated liabilities.
More cash than debt $70m of cash against $10m of debt.
Debt below 40% of shareholders' equity Debt is 20% of equity.
Debt burden no higher than five years ago Debt to equity moved from 1% to 20% over five years.
A year's operating cash flow covers at least 20% of debt −$112m of operating cash flow against $10m of debt.
Operating profit covers interest at least five times over Operating income of −$318m against $1m of interest.

From Kura Oncology, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Compare with peers

Head to head: ADCT vs KURA ASMB vs KURA AAPG vs KURA

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Kura Oncology, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Kura Oncology, Inc.